Channel Islands Alzheimer's Institute Receives $120,000 Donation
Posted on: Wednesday, 17 October 2007, 09:00 CDT
CAMARILLO, Calif., Oct. 17 /PRNewswire/ -- The Channel Islands Alzheimer's Institute recently received a $120,000 donation from Cardax Pharmaceuticals. The money will be received in four payments of $30,000 each beginning now through 2008.
The Channel Islands Alzheimer's Institute is located on the campus of California State University Channel Islands.
Included in the $120,000 donation are at least two student research scholarships for $6,000 each to be used for the student recipients' fees and expenses over two semesters.
"We are gratified that Cardax Pharmaceuticals saw the potential in the drug discovery work of our institute," said Gilbert M. Rishton, Ph.D., founding scientist and director of the Channel Islands Alzheimer's Institute. "These funds will support our ongoing work in drug discovery for neurodegeneration and on the role that certain dietary antioxidants might play in the prevention of cognitive decline and Alzheimer's disease".
Cardax Pharmaceuticals, located in Aiea, Hawaii, develops antioxidant compounds as drug candidates for cardiovascular and inflammatory disease. Cardax Pharmaceuticals has identified a potent antioxidant found in krill and wild salmon, astaxanthin, as being effective in models of cardiovascular and inflammatory disease. The Cardax Pharmaceutical drug candidate is a novel and improved derivative of astaxanthin that is poised for human testing in 2008.
The Channel Islands Alzheimer's Institute has been created to conduct drug discovery research, potentially toward a treatment for the disease that has become so prevalent throughout the world today. According to the Alzheimer's Association, it is estimated that nearly 14 million people worldwide currently suffer from Alzheimer's Disease. By 2050, that number is expected to increase to 45 million. The Channel Islands Alzheimer's Institute will provide opportunities for faculty and students to discover new chemical compounds that will inhibit the neurodegenerative component of Alzheimer's disease.
For more information on the Channel Islands Alzheimer's Institute, its projects and science, contact Gilbert M. Rishton, founding scientist, by e- mail, gilbert.rishton@csuci.edu.
For media inquires about this donation or the Channel Islands Alzheimer's Institute contact Ceal Potts, communications specialist at CSUCI, 805-437-8940 or cecilia.potts@csuci.edu.
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com/.
Channel Islands Alzheimer's Institute
CONTACT: Gilbert M Rishton of Channel Islands Alzheimer's Institute,+1-310-924-9466
Source: PRNewswire
Related Articles
- Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
- Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development Announce Five-Year Collaboration Targeted to Accelerate TB Treatment R&D
- Emergence of Drugs From Elan/Wyeth, Eli Lilly, Myriad Genetics and Medivation Will Drive the Alzheimer's Disease Drug Market to Nearly Triple By 2017
- Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease
- EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases
- Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort
- Register Now for the 8th International Conference on Alzheimer's Disease Drug Discovery
- Research and Markets: Central Nervous System - Alzheimer Disease Drug Pipeline Report
- Anti-inflammatory Function of Alzheimer's Disease Drugs Revealed
 |
 |
User Comments (0)
RSS Feeds